Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 476 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL MOST POPULAR Embracing Bravery When You Have a Genetic Cancer Disease January 13, 2021 New on NCI’s Websites for December 2022 December 27, 2022 After Saving Thousands of Dogs, Tragedy Strikes Famed Rescue Family January 4, 2022 Study Links Breast Cancer Spread to Newly Discovered RNA Splicing Mechanism May 21, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Tegafur Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer... Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS... Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe
